Synapse - Works

Results (5608)

The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer

Meeting Abstract

Yoshikawa, Y.; Wang, X. V.; Chen, Y. H.; Mazzu, Y. Z.; Chakraborty, G.; Jehane, L. E.; Rajanala, S. H.; Hirani, R.; Nandakumar, S.; Stopsack, K. H.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Tannir, N. M.; McDermott, D. F.; Escudier, B.; Hammers, H. J.; Aren, O. R.; Plimack, E. R.; Barthelemy, P.; Neiman, V.; George, S.; Porta, C.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)

Meeting Abstract

Taplin, M. E.; Gleave, M.; Evans, C. P.; Efstathiou, E.; Kantoff, P. W.; Ross, A.; Shore, N. D.; Briganti, A.; Hadaschik, B. A.; Heidenreich, A.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Tran, B.; Horvath, L.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Roncolato, F.; Autio, K. A.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Trends in management and outcomes in patients with upper tract urothelial carcinoma following radical nephrouretectomy at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Wong, N. C.; Assel, M.; Tracey, A.; Alvim, R.; Almassi, N.; Singla, N.; Clinton, T. N.; Chesnut, G. T.; Sjoberg, D. D.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101

Meeting Abstract

Voss, M. H.; Motzer, R. J.; Albiges, L.; Rini, B. I.; Schmidinger, M.; Larkin, J. M. G.; Haanen, J. B. A. G.; Kollmannsberger, C. K.; Campbell, M. T.; Grimm, M. O.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Sartor, A. O.; Morris, M. J.; Messman, R.; Krause, B. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US)

Meeting Abstract

Scher, H. I.; Saad, F.; Mehra, M.; Nair, S.; Dearden, L.; Potluri, R. C.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Fleming, M. T.; Molina, A. M.; Wolf, S. P.; de Leeuw, R.; Fernandez, C.; Kang, P.; Southwell, T.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy

Meeting Abstract

Sarfaty, M.; Teo, M. Y.; Al-Ahmadie, H.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Solit, D. B.; Ratna, N.; Regazzi, A. M.; Hechtman, J. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save